 |
|
Mayo Clinic researchers use magnetic attraction to improve stents, reduce blood clot risk
November 03, 2006ROCHESTER, Minn. - Mayo Clinic heart researchers have devised a new strategy to improve the effectiveness and safety of heart stents, which are used to open narrowed blood vessels and have been the recent subject of clotting concerns. Their novel approach is based on magnetizing healing cells from the patient's blood so the cells are quickly drawn to magnetically coated stents.
The research report appears in the Nov. 7 issue of the Journal of the American College of Cardiology ( http://content.onlinejacc.org/ ). The Mayo team describes encouraging results from preclinical testing.
In the study, the cells were extracted from blood, and tiny iron-based paramagnetic particles were placed within the cells. Each stent was implanted through a tube (catheter) threaded through the blood vessels. Researchers then introduced the iron-tagged cells back into the blood vessel to test how well the magnetized stents captured the cells.
Because the healing cells - also known as endothelial progenitor cells derived from circulating blood - naturally fight blood clot formation, their swift magnetically guided arrival to the stent may reduce the chances of blood clot formation by lining the site fully and quickly, Mayo researchers say.
Results show a sixfold to 30-fold improvement in the magnetized stents' performance in capturing the healing endothelial cells, compared to the standard stents' ability to do so.
"The ability to rapidly coat implanted devices with living cells could accelerate local tissue healing and thereby reduce the risk of blood clot formation," says cardiologist Gurpreet Sandhu, M.D., Ph.D., lead investigator. "Our approach of magnetic cell targeting is the next generation of strategies for improving the safety of stents - and it appears that magnetic forces may provide an elegant solution for cell capture. Additionally, this new magnetic targeting technology can be adapted to develop new cell-, gene- and drug-based treatments for cancer and other human diseases."
Dr. Sandhu adds that, while encouraging, the method is still experimental and not ready to be used on human patients. Researchers are refining their approach, including developing new biomaterials.
Significance of the Mayo Research
"Many people are currently concerned about the risk of blood clots associated in a small percentage of patients with the use of drug-eluting stents," says cardiologist and cardiac researcher Robert Simari, M.D., who co-authored the paper. "Our approach holds the potential to overcome the limitations of the current drug-eluting stent technology because we address the basic conditions of clot formation. One of the reasons clots can form in drug-eluting stent patients is that the area surrounding the stent is not relined fully or quickly enough with the cells in the body, called endothelial cells, that naturally fight blood clots. Our system delivers endothelial cells right where they need to be, rapidly, with the potential for limiting clot formation."
How It Works
Multiple steps led to the development of the new Mayo magnetic cell targeting stent system. For example, the researchers had to devise:
- a way to successfully get endothelial cells derived from blood and grown in lab dishes to live and proliferate when tagged with tiny amounts of magnetically responsive material known as iron-based paramagnetic microspheres.
- specially fabricated stainless steel stents coated with magnetic materials that demonstrated excellent ability to capture the magnetically tagged endothelial cells.
Mayo Clinic
Because the healing cells - also known as endothelial progenitor cells derived from circulating blood - naturally fight blood clot formation, their swift magnetically guided arrival to the stent may reduce the chances of blood clot formation by lining the site fully and quickly, Mayo researchers say.
Results show a sixfold to 30-fold improvement in the magnetized stents' performance in capturing the healing endothelial cells, compared to the standard stents' ability to do so.
"The ability to rapidly coat implanted devices with living cells could accelerate local tissue healing and thereby reduce the risk of blood clot formation," says cardiologist Gurpreet Sandhu, M.D., Ph.D., lead investigator. "Our approach of magnetic cell targeting is the next generation of strategies for improving the safety of stents - and it appears that magnetic forces may provide an elegant solution for cell capture. Additionally, this new magnetic targeting technology can be adapted to develop new cell-, gene- and drug-based treatments for cancer and other human diseases."
Dr. Sandhu adds that, while encouraging, the method is still experimental and not ready to be used on human patients. Researchers are refining their approach, including developing new biomaterials.
Significance of the Mayo Research
"Many people are currently concerned about the risk of blood clots associated in a small percentage of patients with the use of drug-eluting stents," says cardiologist and cardiac researcher Robert Simari, M.D., who co-authored the paper. "Our approach holds the potential to overcome the limitations of the current drug-eluting stent technology because we address the basic conditions of clot formation. One of the reasons clots can form in drug-eluting stent patients is that the area surrounding the stent is not relined fully or quickly enough with the cells in the body, called endothelial cells, that naturally fight blood clots. Our system delivers endothelial cells right where they need to be, rapidly, with the potential for limiting clot formation."
How It Works
Multiple steps led to the development of the new Mayo magnetic cell targeting stent system. For example, the researchers had to devise:
- a way to successfully get endothelial cells derived from blood and grown in lab dishes to live and proliferate when tagged with tiny amounts of magnetically responsive material known as iron-based paramagnetic microspheres.
- specially fabricated stainless steel stents coated with magnetic materials that demonstrated excellent ability to capture the magnetically tagged endothelial cells.
Mayo Clinic
Stents Current Events and Stents News RSSYour Own Stem Cells Can Treat Heart Disease
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.
Higher carotid arterial stenting rates associated with poorer clinical outcomes
Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine.
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.
Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
New type of sirolimus-eluting stent demonstrates superior results
A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.
Laser processes promise better artificial joints, arterial stents
Researchers are developing technologies that use lasers to create arterial stents and longer-lasting medical implants that could be manufactured 10 times faster and also less expensively than is now possible.
Stent for life initiative
Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
More Stents Current Events and Stents News Articles
 |
Handbook of Coronary Stents by Patrick W. Serruys (Editor), Benno J. Rensing (Editor) Erasmus Univ., Rotterdam, The Netherlands. Handbook provides details of all the specifications of the currently available stents and illustrates each chapter with case studies and photographs of the stents themselves. Previous edition: c2000. |
 |
Drug-eluting Stents: Are they Safe? Drug-eluting stents are metal mesh tubes coated with medication that keep arteries from re-blocking after angioplasty. These devices have been the solution for millions of people around the world. However, recent studies have raised concerns about associated risks. Join Dr. Yeung and colleagues as they discuss the safety of these popular devices This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Acmi Corporation Stent-1 .028x100cm Ptfe Coated by ACMI Corporation ACMI CORPORATION STENT-1 .028X100CM PTFE COATED : ACMI CORPORATION STENT-1 .028X100CM PTFE COATED |
|
KR3W The Dixon Stent Jacket,Jackets for Men, Medium,Teal by KR3W KR3W The Dixon Stent Jacket,Jackets for Men: Model is wearing a size MEDIUM The Dixon Stent Jacket has a 100% cotton shell and 100% polyester lining and filling and features a supersoft cotton knit with a lumberjack knit pattern a button-down front and two buttoned chest pockets. By KR3W | |
 |
Stents and Sensibility Starring: Dr. James Ferguson Directed By: John Siceloff Also With: John Siceloff (Producer), David Brancaccio (Writer) |
 |
STENT 'S Beer and Ale Cascading Pub Wall Clock by ZuWEE 9" Black Plastic Wall Clock. Brand new in box. Precision quartz movement operates on one AA battery (not included). This is not a lighted clock. |
![Discotheque [2-Track Single]](http://ecx.images-amazon.com/images/I/51RtqQSEeUL._SL160_.jpg) |
Discotheque [2-Track Single] U2 (Performer), Flood (Performer), Mark "Spike" Stent (Performer) U2 Discotheque CD Single: (1) Discotheque (Album Version) 5:08 (2) Discotheque (Radio Edit) 4:34 |
 |
When The Blues Get The Cup Harvey Andrews with Guest Narrator Malcolm Stent (Primary Contributor) |
 |
STENT Street Sign ~ Personalized Family Lastname Sign ~ Gameroom, Basement, Garage Sign Novelty** METAL ALUMINUM by The Lizton Sign Shop STENT Street Sign, A BRAND NEW SIGN!! Made of aluminum and high quality vinyl lettering and graphics this sign is 4 x 18 inches. Made to last for years outdoors the sign is nice enough to display indoors. Comes with two holes pre-punched for easy installation, corners are rounded. |
 |
Phage And the Origins of Molecular Biology, The Centennial Edition by John Cairns (Editor), Gunther S. Stent (Editor), James D. Watson (Editor) This hugely influential book, published in 1966 as a 60th birthday tribute to Max Delbrück, is now republished as The Centennial Edition. On first publication, the book was hailed as "[introducing] into the literature of science, for the first time, a self conscious historical element in which the participants in scientific discovery engage in writing their own chronicle. As such, it is an important document in the history of biology... "(Journal of History of Biology). And in another review it was described as "required reading for every student of experimental biology...[who] will sense the smell and rattle of the laboratory" (Bioscience). The book was a formative influence on many of today s leading scientists. Related Titles from the... |
| © 2009 BrightSurf.com |